deltatrials
Completed PHASE2 NCT00003748

Irinotecan in Treating Patients With Esophageal or Stomach Cancer

Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia

Sponsor: Jonsson Comprehensive Cancer Center

Conditions Esophageal Cancer Gastric Cancer
Interventions irinotecan hydrochloride
Updated 8 times since 2017 Last updated: Jul 30, 2020 Started: Aug 31, 1998 Primary completion: Jun 30, 2000 Completion: Jan 31, 2005

A PHASE2 clinical study on Esophageal Cancer and Gastric Cancer, this trial is completed. The trial is conducted by Jonsson Comprehensive Cancer Center and has accumulated 8 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

  5. Aug 2020 — Sep 2020 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Aug 2020 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jonsson Comprehensive Cancer Center
  • Pharmacia and Upjohn
Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bakersfield, United States, Fullerton, United States, Inglewood, United States, Lancaster, United States, Las Vegas, United States, Long Beach, United States, Los Angeles, United States, Monterey, United States, Monterey Park, United States, Oxnard, United States and 12 more location s